Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
Type:
Application
Filed:
October 23, 2017
Publication date:
February 15, 2018
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MACDIARMID
Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Type:
Application
Filed:
August 11, 2017
Publication date:
February 1, 2018
Applicant:
EnGeneIC Molecular Delivery Pty. Ltd.
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
Type:
Grant
Filed:
June 20, 2007
Date of Patent:
January 30, 2018
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer Macdiarmid
Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
Type:
Grant
Filed:
April 9, 2014
Date of Patent:
January 16, 2018
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
Type:
Grant
Filed:
December 12, 2012
Date of Patent:
December 19, 2017
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
Type:
Application
Filed:
July 28, 2017
Publication date:
November 16, 2017
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Application
Filed:
May 24, 2017
Publication date:
September 14, 2017
Applicant:
EnGeneIC Molecular Delivery Pty Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Type:
Grant
Filed:
December 29, 2015
Date of Patent:
August 15, 2017
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
Type:
Grant
Filed:
October 3, 2014
Date of Patent:
August 15, 2017
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Type:
Grant
Filed:
January 10, 2014
Date of Patent:
January 26, 2016
Assignee:
EnGeneIC Molecular Delivery Pty. Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
Type:
Grant
Filed:
December 8, 2004
Date of Patent:
October 27, 2015
Assignee:
EnGeneIC Molecular Delivery Pty Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer Macdiarmid
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amount of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
June 30, 2015
Assignee:
EnGeneIC Molecular Delivery Pty Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Grant
Filed:
June 7, 2013
Date of Patent:
February 17, 2015
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer Macdiarmid, Toby Hulf
Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Type:
Application
Filed:
January 10, 2014
Publication date:
October 23, 2014
Applicant:
EnGeneIC Molecular Delivery Pty. Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Application
Filed:
March 12, 2014
Publication date:
August 7, 2014
Applicant:
EnGeneIC Molecular Delivery Pty Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer Macdiarmid, Toby Hulf
Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
Type:
Grant
Filed:
January 27, 2005
Date of Patent:
July 8, 2014
Assignee:
Engeneic Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
Type:
Application
Filed:
November 22, 2013
Publication date:
June 5, 2014
Applicant:
ENGENEIC MOLECULAR DELIVERY PTY LTD
Inventors:
HIMANSHU BRAHMBHATT, JENNIFER MACDIARMID
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
May 27, 2014
Assignee:
Engeneic Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Type:
Grant
Filed:
August 25, 2005
Date of Patent:
April 8, 2014
Assignee:
Engeneic Molecular Delivery Pty. Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid